Objective The purpose of this paper is to explore whether prophylactic use of tocilizumab in patients with B-cell malignancies receiving CD19 Chimeric Antigen Receptor T-cell (CAR-T) therapy reduces the incidence of severe Cytokine Release Syndrome (CRS)
Guistolisi, Anna V
core +1 more source
Recommendations for the timing, dosage, and usage of corticosteroids during cytokine release syndrome (CRS) caused by chimeric antigen receptor (CAR)-T cell therapy for hematologic malignancies. [PDF]
Tu S +30 more
europepmc +1 more source
To cytokine release syndrome (CRS) in patients with multiple myeloma (MM): the nursing role
Sheron Tannara Vargas +3 more
openaire +1 more source
BTK Inhibitor Ibrutinib Reduces Bispecific Antibody-Related CRS Without Undermining the Anti-Tumor Efficacy. [PDF]
Cao J +8 more
europepmc +1 more source
Scientific acronyms help expedite communication but if misheard or misunderstood they can cause confusion and delay life-saving interventions. Such is the case with CRS, cytokine release syndrome and CLS, drug-induced capillary leak syndrome two life ...
Ndje, Amandine P +1 more
core
Case Report: Cytokine adsorption during multimodal management of hyperinflammatory toxicities following CAR-T in three patients. [PDF]
Xu H +5 more
europepmc +1 more source
Long-Term Cardiovascular Care After Cytokine Release Syndrome: JACC CardioOncology Primer. [PDF]
Terol B +6 more
europepmc +1 more source
Brendan C. Bender +9 more
openaire +1 more source
When, Where, and How Much: Toward Smarter Design and Delivery of CAR T‑Cell Therapy. [PDF]
Sathiyamoorthy E +2 more
europepmc +1 more source
Evolution of CAR-T Therapy: Functional Engineering, Manufacturing Innovation, and Future In Vivo Strategies. [PDF]
Sakoda Y.
europepmc +1 more source

